1. Home
  2. GBX vs CTY Comparison

GBX vs CTY Comparison

Compare GBX & CTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greenbrier Companies Inc. (The)

GBX

Greenbrier Companies Inc. (The)

SELL

Current Price

$41.83

Market Cap

1.3B

Sector

Industrials

ML Signal

SELL

CTY

City Therapeutics Inc. Common Stock

N/A

Current Price

$19.59

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GBX
CTY
Founded
1974
2023
Country
United States
United States
Employees
N/A
N/A
Industry
Railroads
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.0B
IPO Year
1996
2026

Fundamental Metrics

Financial Performance
Metric
GBX
CTY
Price
$41.83
$19.59
Analyst Decision
Sell
Strong Buy
Analyst Count
3
3
Target Price
★ $39.67
$37.33
AVG Volume (30 Days)
★ 554.0K
238.1K
Earning Date
10-26-2026
11-27-2026
Dividend Yield
★ 3.25%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 2.49
N/A
Revenue
★ $2,461,100,000.00
N/A
Revenue This Year
$17.81
$62.96
Revenue Next Year
$9.98
$7.47
P/E Ratio
$16.81
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$36.35
$15.81
52 Week High
$59.19
$22.65

Technical Indicators

Market Signals
Indicator
GBX
CTY
Relative Strength Index (RSI) 55.31 44.84
Support Level $41.42 $15.81
Resistance Level $44.24 $22.65
Average True Range (ATR) 1.65 2.07
MACD 0.38 -0.18
Stochastic Oscillator 64.43 46.93

Price Performance

Historical Comparison
GBX
CTY

About GBX Greenbrier Companies Inc. (The)

Greenbrier Companies Inc supplies equipment and services to international freight transportation markets, designing and marketing freight railcars in North America, Europe, and Brazil through subsidiaries and joint ventures. It provides railcar wheel services, parts, maintenance, and conversion services in North America. The company owns a lease fleet sourced mainly from its manufacturing operations and offers railcar management, regulatory compliance, and leasing services to railroads and owners. It operates two segments: Manufacturing and Leasing & Fleet Management, with the majority of revenue from Manufacturing. The company operates in the U.S. and internationally, with the majority of revenue from the U.S. market.

About CTY City Therapeutics Inc. Common Stock

City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.

Share on Social Networks: